排序方式: 共有17条查询结果,搜索用时 0 毫秒
1.
Doreen A. Ezeife MD Francois Dionne PhD Aline Fusco Fares MD Ellen Laura Rose Cusano MD Rouhi Fazelzad BSc MISt Wenzie Ng BSc MPharm RPh Don Husereau BSc Pharm MSc Farzad Ali BPharm MSc Christina Sit MSc Barry Stein B.Com BCL LLB Jennifer H. Law MSc Lisa Le MSc Peter Michael Ellis MD MMed PhD Scott Berry MD Stuart Peacock PhD Craig Mitton PhD Craig C. Earle MD Kelvin K. W. Chan MD PhD Natasha B. Leighl MD MMSc 《Cancer》2020,126(7):1530-1540
2.
3.
4.
Zoratti Michael J. Pickard A. Simon Stalmeier Peep F. M. Ollendorf Daniel Lloyd Andrew Chan Kelvin K W Husereau Don Brazier John E. Krahn Murray Levine Mitchell Thabane Lehana Xie Feng 《The European journal of health economics》2021,22(5):723-733
The European Journal of Health Economics - Published health utility studies are increasingly cited in cost–utility analyses to inform reimbursement decision-making. However, there is limited... 相似文献
5.
Husereau Don Drummond Michael Augustovski Federico de Bekker-Grob Esther Briggs Andrew H. Carswell Chris Caulley Lisa Chaiyakunapruk Nathorn Greenberg Dan Loder Elizabeth Mauskopf Josephine Mullins C. Daniel Petrou Stavros Pwu Raoh-Fang Staniszewska Sophie 《The European journal of health economics》2022,23(8):1309-1317
The European Journal of Health Economics - Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health... 相似文献
6.
7.
Yuti P. Patel Donald Husereau Natasha B. Leighl Barbara Melosky Julian Nam 《Current oncology (Toronto, Ont.)》2021,28(6):5278
BACKGROUND AND OBJECTIVES: Molecular genetic testing using tissue biopsies can be challenging for patients due to unfavorable tumor sites, the invasive nature of a tissue biopsy, and the added time of booking a repeat biopsy (re-biopsy). Centers in Canada have found insufficient tissue rates to be approximately 10%, and even among successful biopsies, insufficient DNA in tissue samples is approximately 16%, triggering the lengthy process of re-biopsies. Using aNSCLC as an example, this study sought to characterize the health and budget impact of alternative liquid-biopsy(LBx)-based comprehensive genomic profile (CGP) testing in tissue-limited patients (TL-LBx-CGP) from a Canadian publicly funded healthcare perspective. MATERIAL AND METHODS: An economic model was developed to estimate the incremental cost and life-years gained as a population associated with adopting TL-LBx-CGP. The eligible patient population was modeled using a top-down epidemiological approach based on the published literature and expert clinician input. Treatment allocation was modeled based on biomarker prevalence in the published literature, and the availability of funded therapies. Costs included molecular testing, as well as drug, administrative, and supportive costs, and relevant health data included median overall survival and median progression-free survival data. RESULTS: Incorporation of TL-LBx-CGP demonstrated an overall impact of $14.7 million with 168 life-years gained to the Canadian publicly funded healthcare system in the 3-year time horizon. 相似文献
8.
Antibodies tagged with enzymes, e.g. horseradish peroxidase (HRPO) are used extensively in a broad range of immunoassay, immunohistochemical, and prodrug-based immunotherapeutic applications. These antibodies may be polyclonal, monoclonal, bispecific or genetically engineered in origin. Often, purification of the antibody is the single greatest obstacle to obtaining immunoprobes with high specific activity [Milstein and Cuello, Nature 305 (1983) 537]. We have circumvented this problem by utilising benzhydroxamic acid-agarose to purify the antibodies tagged with HRPO as a preformed immune complex. Benzhydroxamic acid has been shown to have affinity for the active site of HRPO [de Ropp et al., Biochemistry 38 (1999) 1077]. A preliminary ammonium sulfate precipitation of 250 ml of bispecific antibody supernatant was performed and the pellet resuspended and dialysed against phosphate buffer (pH 7.0). This fraction was incubated with HRPO, then loaded on the affinity column which was washed, and the labelled bispecfic monoclonal antibodies were eluted under mild conditions (borate buffer pH 9.0). The effective yield of this bispecific antibody-HRPO complex was 30 assay plates or 3000 wells. We have also successfully co-purified covalent polyclonal-HRPO conjugates and HRPO-labelled streptavidin using a similar strategy to obtain enzyme-labelled probes with high specific activities for a multitude of applications. 相似文献
9.
Don Husereau Michael Drummond Stavros Petrou Chris Carswell David Moher Dan Greenberg Federico Augustovski Andrew H. Briggs Josephine Mauskopf Elizabeth Loder 《The European journal of health economics》2013,14(3):367-372
Economic evaluations of health interventions pose a particular challenge for reporting. There is also a need to consolidate and update existing guidelines and promote their use in a user friendly manner. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement is an attempt to consolidate and update previous health economic evaluation guidelines efforts into one current, useful reporting guidance. The primary audiences for the CHEERS statement are researchers reporting economic evaluations and the editors and peer reviewers assessing them for publication. The need for new reporting guidance was identified by a survey of medical editors. A list of possible items based on a systematic review was created. A two round, modified Delphi panel consisting of representatives from academia, clinical practice, industry, government, and the editorial community was conducted. Out of 44 candidate items, 24 items and accompanying recommendations were developed. The recommendations are contained in a user friendly, 24 item checklist. A copy of the statement, accompanying checklist, and this report can be found on the ISPOR Health Economic Evaluations Publication Guidelines Task Force website (www.ispor.org/TaskForces/EconomicPubGuidelines.asp). We hope CHEERS will lead to better reporting, and ultimately, better health decisions. To facilitate dissemination and uptake, the CHEERS statement is being co-published across 10 health economics and medical journals. We encourage other journals and groups, to endorse CHEERS. The author team plans to review the checklist for an update in five years. 相似文献
10.
Don Husereau William Dempster Adrienne Blanchard Johanne Chambers 《Value in health》2014,17(8):888-894
Canada has a unique system of public drug coverage and reimbursement characterized by a centralized review agency that makes funding recommendations along with decentralized authority for delivering health care across 10 provinces and three territories. There has been a significant increase in price negotiation for new pharmaceuticals in the past 10 years, first by individual provinces and now through a collective price negotiation process called the “Pan-Canadian Pharmaceutical Alliance.” As of February 2014, the Pan-Canadian Pharmaceutical Alliance has already completed 32 negotiations despite still being in a formative stage; it is anticipated that a formal process will be developed in the coming year. In this article, we describe the evolution of price negotiation in Canada and identify several opportunities for improvement of the current process, including the incorporation of economic considerations into price negotiation. 相似文献